Trading Signals: ADMS Stock Price Prediction and Forecast (Thu. Apr. 10, 2014 - Mon. Aug. 9, 2021)(Adamas Pharmaceuticals Inc)
| ADMS latest price $6.3400 (0.32%) ($6.2300 - $6.4200) on Wed. May. 1, 2019. | |
| | Trend Analysis and Forecast | | | Average Daily Percentage Swing | 4.94% (three month average) | RSI | 34 | Latest Price | $6.3400(0.32%) | Stocks Behave Similarly | Similar Stock List | Daily Trend | ADMS advances 0.2% a day on average for past five trading days. | Weekly Trend | ADMS declines -1.5% a week on average for past two weeks. | Market Behavior | Broad based sell-off for large cap. Broad based sell-off for small cap. | Correlated ETFs | Broad market will support ADMS advance at 0% a week (0% probability) XOP(12%) OIH(11%) EWI(9%) ONLN(9%) XBI(9%) | Factors Impacting ADMS price | ADMS will decline at least -2.47% in a week (0% probabilities). UUP(-10%) BNDX(-10%) GDX(-9%) GLD(-8%) GDXJ(-7%) | Explanation | The rally is not sustainable and not supported by the broad market. | | | | | Relative Volatility | | | | Market Trend Strength | -2.47% (StdDev 4.94%) | Hourly BBV | 0 () | Intraday Trend | -0.6% | | | |
|
Resistance Level | $6.5 | 5 Day Moving Average | $6.36(-0.31%) | 10 Day Moving Average | $6.34(0%) | 20 Day Moving Average | $6.5(-2.46%) | To recent high | -47.8% | To recent low | 1.4% | Market Cap | $179m | | | | Adamas Pharmaceuticals, Inc. engages in discovery and development of chrono-synchronous therapies for chronic neurologic disorders. Its products include GOCOVRI, ADS-5012, ADS-4101, and Namzaric. GOCOVRI is indicated for the treatment of dyskinesia in patients with Parkinson’s disease receiving levodopa-based therapy. ADS-5102 is a treatment for walking impairment in patients with multiple sclerosis. ADS-401 treats partial onset seizures in patients with epilepsy. Namzaric is a drug treatment for moderate to severe Alzheimer's disease. The company was founded by Gregory T. Went on November 15, 2000 and is headquartered in Emeryville, CA. |